Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Conditions:   Multiple Endocrine Neoplasia;   Recurrent Thyroid Gland Carcinoma;   Thyroid Gland Medullary CarcinomaInterventions:   Drug: Sorafenib Tosylate;   Other: Pharmacological Study;   Other: Laboratory Biomarker AnalysisSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified March 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials